Hemoglobinopathy Market (By Type: Thalassemia [Beta Thalassemia, Alpha Thalassemia], Sickle Cell Disease, Other Hb Variants Diseases; By Therapy: Thalassemia [Beta Thalassemia, Alpha Thalassemia], Sickle Cell Disease, Other Hb Variants Diseases; By Diagnosis: Thalassemia [Beta Thalassemia, Alpha Thalassemia], Sickle Cell Disease, Other Hb variants diseases) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format: PDF | Status: Published | Pages : 190

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Hemoglobinopathy
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Hemoglobinopathy Market By Type
1.2.2.1. Global Hemoglobinopathy Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Hemoglobinopathy Market Revenue Share By Type in 2017
1.2.2.3. Thalassemia
1.2.2.4. Beta Thalassemia
1.2.2.5. Alpha Thalassemia
1.2.2.6. Sickle Cell Disease
1.2.2.7. Other Hb Variants Diseases
1.2.3. Hemoglobinopathy Market By Therapy
1.2.3.1. Global Hemoglobinopathy Market Revenue and Growth Rate Comparison By Therapy (2015-2026)
1.2.3.2. Thalassemia
1.2.3.3. Beta Thalassemia
1.2.3.4. Alpha Thalassemia
1.2.3.5. Sickle Cell Disease
1.2.3.6. Other Hb Variants Diseases
1.2.4. Hemoglobinopathy Market By Diagnosis
1.2.4.1. Global Hemoglobinopathy Market Revenue and Growth Rate Comparison By Diagnosis (2015-2026)
1.2.4.2. Thalassemia
1.2.4.3. Beta Thalassemia
1.2.4.4. Alpha Thalassemia
1.2.4.5. Sickle Cell Disease
1.2.4.6. Other Hb variants diseases
1.2.5. Hemoglobinopathy Market by Geography
1.2.5.1. Global Hemoglobinopathy Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Hemoglobinopathy Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Hemoglobinopathy Major Manufacturers in 2017
3.3. R&D Status and Technology Type of Global Hemoglobinopathy Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Hemoglobinopathy Major Manufacturers in 2017

CHAPTER 4. HEMOGLOBINOPATHY MARKET BY BY TYPE

4.1. Global Hemoglobinopathy Revenue By Type
4.2. Thalassemia
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Beta Thalassemia
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Alpha Thalassemia
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Sickle Cell Disease
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Other Hb Variants Diseases
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. HEMOGLOBINOPATHY MARKET BY THERAPY

5.1. Global Hemoglobinopathy Revenue By Therapy
5.2. Thalassemia
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Beta Thalassemia
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Alpha Thalassemia
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Sickle Cell Disease
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Other Hb Variants Diseases
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. HEMOGLOBINOPATHY MARKET BY DIAGNOSIS

6.1. Global Hemoglobinopathy Revenue By Diagnosis
6.2. Thalassemia
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Beta Thalassemia
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Alpha Thalassemia
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Sickle Cell Disease
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. Other Hb variants diseases
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA HEMOGLOBINOPATHY MARKET BY COUNTRY

7.1. North America Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Hemoglobinopathy Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Hemoglobinopathy Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE HEMOGLOBINOPATHY MARKET BY COUNTRY

8.1. Europe Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Hemoglobinopathy Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC HEMOGLOBINOPATHY MARKET BY COUNTRY

9.1. Asia-Pacific Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Hemoglobinopathy Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA HEMOGLOBINOPATHY MARKET BY COUNTRY

10.1. Latin America Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Hemoglobinopathy Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST HEMOGLOBINOPATHY MARKET BY COUNTRY

11.1. Middle East Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Hemoglobinopathy Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA HEMOGLOBINOPATHY MARKET BY COUNTRY

12.1. Africa Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Hemoglobinopathy Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Alnylam Pharmaceuticals
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Gamida Cell
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Global Blood Therapeutics Inc.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. bluebird media Inc.
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Emmaus Life Sciences Inc
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Sanofi
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Prolong Pharmaciens
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Celgene Corporation
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Others
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope


Cart Summary